Nonfasting versus fasting lipid profile for cardiovascular risk prediction.

[1]  F. Kronenberg,et al.  Quantifying Atherogenic Lipoproteins: Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLM. , 2018, Clinical chemistry.

[2]  B. Nordestgaard,et al.  U-shaped relationship of HDL and risk of infectious disease: two prospective population-based cohort studies , 2018, European heart journal.

[3]  F. Chen,et al.  Effects of Anacetrapib in Patients With Atherosclerotic Vascular Disease , 2018 .

[4]  B. Nordestgaard.  A Test in Context: Lipid Profile, Fasting Versus Nonfasting. , 2017, Journal of the American College of Cardiology.

[5]  B. Nordestgaard,et al.  Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: two prospective cohort studies , 2017, European heart journal.

[6]  Eliot A Brinton,et al.  AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE. , 2017, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[7]  G. Lip,et al.  Current Understanding of Atherogenesis. , 2017, The American journal of medicine.

[8]  M. Scartezini,et al.  Positioning about the Flexibility of Fasting for Lipid Profiling , 2017, Arquivos brasileiros de cardiologia.

[9]  R. Havel,et al.  The Online Metabolic and Molecular Bases of Inherited Disease > 114 : Introduction : Structure and Metabolism of Plasma Lipoproteins , 2017 .

[10]  Børge G Nordestgaard,et al.  Nonfasting Mild-to-Moderate Hypertriglyceridemia and Risk of Acute Pancreatitis. , 2016, JAMA internal medicine.

[11]  G. Francis,et al.  2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. , 2016, The Canadian journal of cardiology.

[12]  B. Nordestgaard,et al.  Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology , 2016, Journal of Lipid Research.

[13]  A. Hoes,et al.  2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. , 2016, European heart journal.

[14]  Brian A Ference,et al.  Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis. , 2016, JAMA.

[15]  James H Derzon,et al.  Lipoprotein Biomarkers and Risk of Cardiovascular Disease: A Laboratory Medicine Best Practices (LMBP) Systematic Review. , 2016, The journal of applied laboratory medicine.

[16]  P. McFarlane,et al.  Hypertension Canada's 2016 Canadian Hypertension Education Program Guidelines for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. , 2016, The Canadian journal of cardiology.

[17]  F. Kronenberg,et al.  Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points—a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Med , 2016, Clinical chemistry.

[18]  P. O'Malley,et al.  Management of Dyslipidemia for Cardiovascular Disease Risk Reduction: Synopsis of the 2014 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline , 2015, Annals of Internal Medicine.

[19]  W. Guan,et al.  Use of Lipoprotein Particle Measures for Assessing Coronary Heart Disease Risk Post-American Heart Association/American College of Cardiology Guidelines: The Multi-Ethnic Study of Atherosclerosis , 2015, Arteriosclerosis, thrombosis, and vascular biology.

[20]  A. Khera,et al.  HDL cholesterol efflux capacity and incident cardiovascular events. , 2014, The New England journal of medicine.

[21]  S. Bangalore,et al.  Prognostic Value of Fasting Versus Nonfasting Low-Density Lipoprotein Cholesterol Levels on Long-Term Mortality: Insight From the National Health and Nutrition Examination Survey III (NHANES-III) , 2014, Circulation.

[22]  B. Nordestgaard,et al.  Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. , 2014, The New England journal of medicine.

[23]  He Zhang,et al.  Loss-of-function mutations in APOC3, triglycerides, and coronary disease. , 2014, The New England journal of medicine.

[24]  R. Virmani,et al.  Mechanisms of Plaque Formation and Rupture , 2014 .

[25]  B. Nordestgaard,et al.  Lipoprotein(a): fasting and nonfasting levels, inflammation, and cardiovascular risk. , 2014, Atherosclerosis.

[26]  B. Nordestgaard,et al.  Low nonfasting triglycerides and reduced all-cause mortality: a mendelian randomization study. , 2014, Clinical chemistry.

[27]  S. Hazen,et al.  Paradoxical Association of Enhanced Cholesterol Efflux With Increased Incident Cardiovascular Risks , 2013, Arteriosclerosis, thrombosis, and vascular biology.

[28]  B. Nordestgaard,et al.  Remnant cholesterol as a causal risk factor for ischemic heart disease. , 2013, Journal of the American College of Cardiology.

[29]  Jennifer G. Robinson,et al.  Reprint: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. , 2013, Journal of the American Pharmacists Association : JAPhA.

[30]  C. Naugler,et al.  Fasting time and lipid levels in a community-based population: a cross-sectional study. , 2012, Archives of internal medicine.

[31]  John Spertus,et al.  Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study , 2012, The Lancet.

[32]  J. Gallacher,et al.  Lipid-related markers and cardiovascular disease prediction. , 2012, JAMA.

[33]  N. Poulter,et al.  The Anglo-Scandinavian Cardiac Outcomes Trial: 11-year mortality follow-up of the lipid-lowering arm in the U.K. , 2011, European heart journal.

[34]  M. Steiner,et al.  Fasting Might Not Be Necessary Before Lipid Screening: A Nationally Representative Cross-sectional Study , 2011, Pediatrics.

[35]  Moshe Levi,et al.  Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. , 2011, Circulation.

[36]  C. Furberg,et al.  A Meta-Analysis of Low-Density Lipoprotein Cholesterol, Non-High-Density Lipoprotein Cholesterol, and Apolipoprotein B as Markers of Cardiovascular Risk , 2011, Circulation. Cardiovascular quality and outcomes.

[37]  B. Nordestgaard,et al.  Nonfasting lipids, lipoproteins, and apolipoproteins in individuals with and without diabetes: 58 434 individuals from the Copenhagen General Population Study. , 2011, Clinical chemistry.

[38]  Robert L Wilensky,et al.  Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. , 2011, The New England journal of medicine.

[39]  M. Gnant,et al.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010 .

[40]  A. Ogawa,et al.  Comparison of low-density lipoprotein cholesterol concentrations measured by a direct homogeneous assay and by the Friedewald formula in a large community population. , 2010, Clinica chimica acta; international journal of clinical chemistry.

[41]  J. Borén,et al.  Lipoprotein(a) as a cardiovascular risk factor: current status , 2010, European heart journal.

[42]  J. Danesh,et al.  Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies , 2010, The Lancet.

[43]  R. Collins,et al.  Genetic variants associated with Lp(a) lipoprotein level and coronary disease. , 2009, The New England journal of medicine.

[44]  J. Danesh,et al.  Major lipids, apolipoproteins, and risk of vascular disease. , 2009, JAMA.

[45]  Børge G Nordestgaard,et al.  Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. , 2009, JAMA.

[46]  P. Ridker,et al.  Comparison of LDL cholesterol concentrations by Friedewald calculation and direct measurement in relation to cardiovascular events in 27,331 women. , 2009, Clinical chemistry.

[47]  L. Hilsted,et al.  [Plasma lipids in non-fasting patients and signal values of laboratory results]. , 2009, Ugeskrift for laeger.

[48]  Sridevi Devaraj,et al.  Apolipoprotein B and cardiovascular disease risk: position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices. , 2009, Clinical chemistry.

[49]  Jennifer G. Robinson,et al.  Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk. , 2009, Journal of the American College of Cardiology.

[50]  B. Nordestgaard,et al.  Fasting and Nonfasting Lipid Levels: Influence of Normal Food Intake on Lipids, Lipoproteins, Apolipoproteins, and Cardiovascular Risk Prediction , 2008, Circulation.

[51]  B. Nordestgaard,et al.  Nonfasting triglycerides and risk of ischemic stroke in the general population. , 2008, JAMA.

[52]  Samia Mora,et al.  Fasting Compared With Nonfasting Lipids and Apolipoproteins for Predicting Incident Cardiovascular Events , 2008, Circulation.

[53]  Børge G Nordestgaard,et al.  Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease. , 2008, JAMA.

[54]  B. Nordestgaard,et al.  Extreme Lipoprotein(a) Levels and Risk of Myocardial Infarction in the General Population: The Copenhagen City Heart Study , 2008 .

[55]  A. Sniderman,et al.  Non-HDL cholesterol and apoB in dyslipidaemia. , 2008, Clinical science.

[56]  R. Collins,et al.  Study of the effectiveness of additional reductions in cholesterol and homocysteine (SEARCH): characteristics of a randomized trial among 12064 myocardial infarction survivors. , 2007, American heart journal.

[57]  B. Nordestgaard,et al.  Improving Prediction of Ischemic Cardiovascular Disease in the General Population Using Apolipoprotein B: The Copenhagen City Heart Study , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[58]  J. Danesh,et al.  Triglycerides and the Risk of Coronary Heart Disease: 10 158 Incident Cases Among 262 525 Participants in 29 Western Prospective Studies , 2007, Circulation.

[59]  K. Suckling,et al.  Differential Effects of Low-Density Lipoprotein and Chylomicron Remnants on Lipid Accumulation in Human Macrophages , 2004, Experimental biology and medicine.

[60]  J. Slattery,et al.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. , 1994, Atherosclerosis. Supplements.

[61]  I. Miyamori,et al.  The very low-density lipoprotein (VLDL) receptor: characterization and functions as a peripheral lipoprotein receptor. , 2004, Journal of atherosclerosis and thrombosis.

[62]  AndrewJ. S. Coats.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.

[63]  S. Yusuf.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .

[64]  Børge G Nordestgaard,et al.  Macrophages are associated with lipid-rich carotid artery plaques, echolucency on B-mode imaging, and elevated plasma lipid levels. , 2002, Journal of vascular surgery.

[65]  E. Schaefer,et al.  Comparison of fasting and postprandial plasma lipoproteins in subjects with and without coronary heart disease. , 2001, The American journal of cardiology.

[66]  H. C. Stary,et al.  Natural history and histological classification of atherosclerotic lesions: an update. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[67]  G. Jensen,et al.  Elevated HDL cholesterol is a risk factor for ischemic heart disease in white women when caused by a common mutation in the cholesteryl ester transfer protein gene. , 2000, Circulation.

[68]  W D Wagner,et al.  A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. , 1995, Circulation.

[69]  Scandinavian Simvastatin Survival Study Group.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) , 1994, The Lancet.

[70]  D. Gordon,et al.  High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. , 1989, Circulation.

[71]  D. B. Zilversmit,et al.  Large lipoproteins are excluded from the arterial wall in diabetic cholesterol-fed rabbits. , 1988, Journal of lipid research.

[72]  B. Nordestgaard,et al.  Reduced Atherogenesis in Cholesterol‐fed Diabetic Rabbits: Giant Lipoproteins Do Not Enter the Arterial Wall , 1988, Arteriosclerosis.

[73]  J. Ordovás,et al.  Postprandial plasma lipoprotein changes in human subjects of different ages. , 1988, Journal of lipid research.

[74]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.